Loncastuximab tesirine (ADCT-402) expanded access program (EAP)
ADC Therapeutics is committed to confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families. Medical Affairs delivers scientific data and knowledge of the highest scientific and ethical standards to the healthcare community and the patients we serve.
ADC Therapeutics will consider individual single patient access to loncastuximab tesirine in the United States for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), who cannot be treated by currently available drugs, cell therapy, or clinical trials. Treating physicians must submit their request using the form below. ADC Therapeutics will acknowledge the inquiry within three business days of receipt. ADC Therapeutics will evaluate patients for approval into the program. Access to the investigational drug is subject to ADC Therapeutics and regulatory approval(s).
Questions about ADC Therapeutics’s EAP should be directed to firstname.lastname@example.org.
* Required Fields